<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>399(1)</volume><submitter>Rahim-Mahdy H</submitter><funding>Medizinische Hochschule Hannover (MHH)</funding><pubmed_abstract>Historically prominent in Ayurvedic cultures, turmeric (Curcuma longa), or "Haldi," is renowned for its anti-inflammatory and antioxidant effects, mainly due to its active compounds, curcuminoids. Due to the increasing use of turmeric supplements, this study critically examined 125 preparations across the UK, USA, India, Australia, and Germany and evaluated their compliance with evidence-based recommendations. Results reveal significant regulatory and labeling inconsistencies across countries, with 34% of preparations failing to disclose the active curcuminoid content. This lack of dosage regulation is especially concerning when considering the ongoing research into advanced delivery systems-such as nanoparticles, liposomes, micelles, and phospholipid complexes-which significantly enhance </pubmed_abstract><journal>Naunyn-Schmiedeberg's archives of pharmacology</journal><pagination>1315-1346</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12894154</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA.</pubmed_title><pmcid>PMC12894154</pmcid><pubmed_authors>Seifert R</pubmed_authors><pubmed_authors>Rahim-Mahdy H</pubmed_authors></additional><is_claimable>false</is_claimable><name>A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA.</name><description>Historically prominent in Ayurvedic cultures, turmeric (Curcuma longa), or "Haldi," is renowned for its anti-inflammatory and antioxidant effects, mainly due to its active compounds, curcuminoids. Due to the increasing use of turmeric supplements, this study critically examined 125 preparations across the UK, USA, India, Australia, and Germany and evaluated their compliance with evidence-based recommendations. Results reveal significant regulatory and labeling inconsistencies across countries, with 34% of preparations failing to disclose the active curcuminoid content. This lack of dosage regulation is especially concerning when considering the ongoing research into advanced delivery systems-such as nanoparticles, liposomes, micelles, and phospholipid complexes-which significantly enhance </description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-16T09:40:39.911Z</modification><creation>2026-07-09T10:46:41.938Z</creation></dates><accession>S-EPMC12894154</accession><cross_references><pubmed>40773013</pubmed><doi>10.1007/s00210-025-04392-5</doi></cross_references></HashMap>